These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36732058)

  • 1. Could FAP-Targeted Molecular Imaging Replace
    Kashyap R; Ravi Kumar AS
    J Nucl Med; 2023 Apr; 64(4):623-624. PubMed ID: 36732058
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncologic
    Montilla-Soler JL; Makanji RJ; Barron BJ
    Am J Med; 2018 Apr; 131(4):357-364. PubMed ID: 29274757
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ederhy S; Devos P; Pinna B; Funck-Brentano E; Abbar B; Fenioux C; Cohen AA; Moslehi J; Bretagne M; Allenbach Y; Kharroubi D; Salem JE
    Arch Cardiovasc Dis; 2022 Feb; 115(2):114-116. PubMed ID: 35120869
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on advances in molecular PET in urological oncology.
    Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
    Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PET Research in Clinical Oncology].
    Mitsumoto T; Takabatake M; Inoue K; Fukushi M
    Igaku Butsuri; 2022; 42(2):80-87. PubMed ID: 35768265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [
    Linz C; Brands RC; Kertels O; Dierks A; Brumberg J; Gerhard-Hartmann E; Hartmann S; Schirbel A; Serfling S; Zhi Y; Buck AK; Kübler A; Hohm J; Lapa C; Kircher M
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):3951-3960. PubMed ID: 34050405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of
    Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
    Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging minimal residual disease evaluation in multiple myeloma using [
    Barilà G; Crimì F; Arangio Febbo M; Pavan L; Vedovato S; Cabrelle G; Zanon C; Campi C; Cecchin D; Zucchetta P; Lacognata C; Semenzato G; Zambello R
    Leuk Lymphoma; 2023 Feb; 64(2):503-506. PubMed ID: 36382776
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of FDG PET/MRI and FDG PET/CT in Pediatric Oncology in Terms of Anatomic Correlation of FDG-positive Lesions.
    Uslu-Beşli L; Atay Kapucu LÖ; Karadeniz C; Akdemir ÜÖ; Pinarli FG; Aydos U; Okur A; Kaya Z; Samanci C; Karabacak NI
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):542-550. PubMed ID: 30933019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
    Lee JW; Nam SB; Kim SJ
    Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical
    Childs L; Thompson A; Jones H; Hameeduddin A; Ghufoor K; Adams A
    Clin Imaging; 2018; 49():136-143. PubMed ID: 29414508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On Semiquantitative Methods for Assessing Vascular
    Laffon E; Marthan R
    J Nucl Med; 2022 Feb; 63(2):325-326. PubMed ID: 34475239
    [No Abstract]   [Full Text] [Related]  

  • 13. Imaging spectrum and pitfalls of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with tuberculosis.
    Ito K; Morooka M; Minamimoto R; Miyata Y; Okasaki M; Kubota K
    Jpn J Radiol; 2013 Aug; 31(8):511-20. PubMed ID: 23719763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Counterpoint-No, Not So Fast!
    Moradi F; Iagaru A
    AJR Am J Roentgenol; 2021 Feb; 216(2):307-308. PubMed ID: 32755204
    [No Abstract]   [Full Text] [Related]  

  • 15. Current clinical status of
    Nakajo M; Kajiya Y; Jinguji M; Nakabeppu Y; Nakajo M; Nihara T; Yoshiura T
    Abdom Radiol (NY); 2017 Mar; 42(3):951-961. PubMed ID: 27770160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Government funding of fluorodeoxyglucose positron emission tomography (FDG-PET) in rare urological cancers: better data, better outcomes.
    Xu J; Al Saffar H; O'Brien J; Kelly B; Lawrentschuk N
    BJU Int; 2024 Feb; 133 Suppl 3():8-9. PubMed ID: 37467147
    [No Abstract]   [Full Text] [Related]  

  • 17. Head-to-Head Comparison of [
    Wegen S; van Heek L; Linde P; Claus K; Akuamoa-Boateng D; Baues C; Sharma SJ; Schomäcker K; Fischer T; Roth KS; Klußmann JP; Marnitz S; Drzezga A; Kobe C
    Mol Imaging Biol; 2022 Dec; 24(6):986-994. PubMed ID: 35771317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Imaging of Abdominal Aortic Aneurysms with Positron Emission Tomography: A Systematic Review.
    Baolei G; Can C; Peng L; Yan S; Cheng Y; Hui T; Minzhi L; Daqiao G; Weiguo F
    Eur J Vasc Endovasc Surg; 2021 Dec; 62(6):969-980. PubMed ID: 34696984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-Body [
    Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
    Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review.
    Treglia G; Sadeghi R; Del Sole A; Giovanella L
    Clin Transl Oncol; 2014 Sep; 16(9):770-5. PubMed ID: 24647843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.